MCRB Quote, Financials, Valuation and Earnings

Cellectar Biosciences has a net margin of -- compared to Seres Therapeutics's net margin of --. Seres Therapeutics's return on equity of -- beat Cellectar Biosciences's return on equity of --.

Seres Therapeutics has a consensus price target of $3.82, signalling upside risk potential of 418.23%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 1582.5%. Given that Cellectar Biosciences has higher upside potential than Seres Therapeutics, analysts believe Cellectar Biosciences is more attractive than Seres Therapeutics.

Seres Therapeutics has a beta of 2.186, which suggesting that the stock is 118.578% more volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.963, suggesting its less volatile than the S&P 500 by 3.676%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than Cellectar Biosciences quarterly revenues of --. Seres Therapeutics's net income of -$15.6M is lower than Cellectar Biosciences's net income of -$14.7M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.93x versus 730.55x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Seres Therapeutics's net margin of -49.65%. Seres Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Seres Therapeutics has a consensus price target of $3.82, signalling upside risk potential of 418.23%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Seres Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Seres Therapeutics is more attractive than NovaBay Pharmaceuticals.

Seres Therapeutics has a beta of 2.186, which suggesting that the stock is 118.578% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Seres Therapeutics's net income of -$15.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.93x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Seres Therapeutics's net margin of -2357.27%. Seres Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Seres Therapeutics has a consensus price target of $3.82, signalling upside risk potential of 418.23%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Palatin Technologies has higher upside potential than Seres Therapeutics, analysts believe Palatin Technologies is more attractive than Seres Therapeutics.

Seres Therapeutics has a beta of 2.186, which suggesting that the stock is 118.578% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Seres Therapeutics's net income of -$15.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.93x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals has a net margin of -- compared to Seres Therapeutics's net margin of -1226.16%. Seres Therapeutics's return on equity of -- beat Syndax Pharmaceuticals's return on equity of -74.65%.

Seres Therapeutics has a consensus price target of $3.82, signalling upside risk potential of 418.23%. On the other hand Syndax Pharmaceuticals has an analysts' consensus of $36.14 which suggests that it could grow by 177.17%. Given that Seres Therapeutics has higher upside potential than Syndax Pharmaceuticals, analysts believe Seres Therapeutics is more attractive than Syndax Pharmaceuticals.

Seres Therapeutics has a beta of 2.186, which suggesting that the stock is 118.578% more volatile than S&P 500. In comparison Syndax Pharmaceuticals has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.546%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. Syndax Pharmaceuticals pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than Syndax Pharmaceuticals quarterly revenues of $7.7M. Seres Therapeutics's net income of -$15.6M is higher than Syndax Pharmaceuticals's net income of -$94.2M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while Syndax Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.93x versus -- for Syndax Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.